Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

>

the enhancement of the apoptotic effect when added to either

vincristine or fludarabine. The other poster reported that in vivo

immunostimulatory responses to ANA773 can be effectively modified by

varying the schedule of dose administration, including every other day

dosing (QOD), and three consecutive days of dosing within each seven

day cycle (3-on, 4-off).

Program Updates and Revised Cash Outlook for 2008

-- ANA598 Development Activities. Based on promising results from the

preclinical evaluation of ANA598, Anadys has made the strategic

decision to accelerate certain non-clinical activities for this

program, including further manufacturing of drug substance and

conducting additional toxicology studies. These studies include a

combination toxicology study with ribavirin that will support the

clinical investigation of ANA598 in combination with interferon and

ribavirin, as well as studies extending the duration of dosing beyond

the recently completed 28 day toxicology study. If ANA598 is

successful in early stage clinical trials, it is anticipated that the

acceleration of these non-clinical activities into 2008 will enable a

more rapid and continuous development path into mid-stage clinical

trials during 2009.

-- ANA773 Development Activities. Anadys continues to explore the safety

and tolerability profile of ANA773 in the ongoing Phase I trial and

expects to identify pharmacologically active doses and establish the

profile of immune stimulation this year, which information will support

the future design of clinical trials of ANA773 (alone or in

combinations) in specific tumor types. While Anadys expects the rate

of enrollment in the ANA773 oncology trial to increase in the coming

quarters, the Company now expects the pac
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... has been recognized as one of the nation’s ... 5000 magazine for the 2nd consecutive year. Inc. ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ...
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Seeing a molecule breathe 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... LSU associate professor of chemistry in the College of ... honor for scientists and engineers in the early stages ... Award for Scientists and Engineers, or PECASE. "I ... award. LSU is a rich environment for accomplishing nanoscience ...
... ... ... ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... ... ... var shortURL = ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
Cached Biology Technology:LSU’s Jayne Garno receives early career award from President 2Atrium Innovations Announces Third Quarter Financial Results of 2010 2Atrium Innovations Announces Third Quarter Financial Results of 2010 3Atrium Innovations Announces Third Quarter Financial Results of 2010 4Atrium Innovations Announces Third Quarter Financial Results of 2010 5Atrium Innovations Announces Third Quarter Financial Results of 2010 6Atrium Innovations Announces Third Quarter Financial Results of 2010 7Atrium Innovations Announces Third Quarter Financial Results of 2010 8Atrium Innovations Announces Third Quarter Financial Results of 2010 9Atrium Innovations Announces Third Quarter Financial Results of 2010 10Atrium Innovations Announces Third Quarter Financial Results of 2010 11Atrium Innovations Announces Third Quarter Financial Results of 2010 12Atrium Innovations Announces Third Quarter Financial Results of 2010 13Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 2Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 3Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 4Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 5Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 6Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 7Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 8
(Date:8/21/2014)... SHELTON, Conn. , Aug. 21, 2014 ... on the growing mobile commerce market, announced today that ... purchase common stock to be issued in its proposed ... been approved for listing on The Nasdaq Capital Market, ... of the common stock and warrants, and will trade ...
(Date:8/21/2014)... A landmark study aimed at improving the food intake, ... long-term care homes is among three projects at the ... grants from the Canadian Institutes of Health Research (CIHR). ... Applied Health Sciences at Waterloo, and a Schlegel research ... two years to investigate why many Canadians living in ...
(Date:8/21/2014)... Saturday to Wednesday, Oct. 18-22, 2014 , ... Harbor Drive, San Diego, CA 92101 , ... other presentations of the latest research in human ... session featuring high-scoring abstracts on rare genetic variants ... cancers, and treatment for sun sensitivity (Saturday, Oct. ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... that resists infection, yet 10% of the world's agricultural ... fungi, and viruses. Understanding how disease resistance works may ... study published online this week in the open-access journal ... how one aspect of the plant immune system is ...
... and separate a wide class of swimming bacteria ... at Argonne National Laboratory, Illinois Institute of technology, ... UK. This device could have enormous applications in ... medical diagnostic kits and bioanalysis. , The technique ...
... person, it triggers a series of biochemical reactions in immune-system ... , Usually, the result is an effective immune response, leading ... recovery. But in the case of some of the world’s ... as well as the influenza virus strain responsible for the ...
Cached Biology News:Researchers develop technique for bacteria crowd control 2New study may show how to forestall a fatal, virus-caused immune-system meltdown 2New study may show how to forestall a fatal, virus-caused immune-system meltdown 3
... Coating Stabilizer has been developed specifically ... immobilized proteins on microwell plates/strips. ... activity of the antibody or protein ... components. Product is filtered at ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: